Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor - a systematic review and meta-analysis

被引：11

作者：

Perdyan, Adrian ^{[1
]}

Spychalski, Piotr ^{[2
]}

Kacperczyk, Justyna ^{[3
]}

Rostkowska, Olga ^{[2
]}

Kobiela, Jarek ^{[2
]}

机构：

[1] Med Univ Gdansk, Dept Gen Endocrine & Transplant Surg, Student Sci Circle, Gdansk, Poland

[2] Med Univ Gdansk, Dept Gen Endocrine & Transplant Surg, Gdansk, Poland

[3] Univ Warmia & Mazury, Students Sci Soc Gen Minimally Invas & Elderly Su, Coll Medium, Olsztyn, Poland

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 154卷

关键词：

colorectal cancer; circulating tumor DNA; KRAS; prognostic Factor; CELL-FREE DNA; ALLELE-SPECIFIC IMBALANCE; CODON; 12; GENE-MUTATIONS; BRAF MUTATIONS; LIQUID BIOPSY; CHEMOTHERAPY; ASSOCIATION; WORSE; CATEGORIZATION;

D O I：

10.1016/j.critrevonc.2020.103065

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Liquid biopsy is a novel tool in oncology. It provides minimally invasive detection of tumor specific DNA. This review summarizes data on presence of circulating tumor DNA in serum or plasma of CRC patients as a potential negative prognostic factor. Materials and Methods: The systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The search was performed using PubMed, Web of Science and Scopus. Results: In total 18 articles with a total of 1779 patients ma the inclusion criteria. Six out of 8 studies found that presence of ctDNA in plasma/serum was associated with inferior overall survival. All 6 studies found that high concentrations of ctDNA in plasma/serum was associated with inferior overall survival. Conclusions: Presence or high concentrations of KRAS mutation in plasma or serum were associated with inferior prognosis. Establishing cut-off concentrations is warranted for further clinical implementation of liquid biopsy.

引用

页数：9

共 63 条

[1]

[Anonymous], 2020, GESUNDE PFLANZ, DOI DOI 10.1007/S10343-020-00536-0

[2] The Prognostic Value of 18F-FDG PET/CT and KRAS Mutation in Colorectal Cancers [J].

Arslan, Esra ;

Aksoy, Tamer ;

Gursu, Riza Umar ;

Dursun, Nevra ;

Cakar, Ekrem ;

Cermik, Tevfik Fikret .

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2020, 29 (01) :17-24

[3] Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology [J].

Benson, Al B., III ;

Venook, Alan P. ;

Cederquist, Lynette ;

Chan, Emily ;

Chen, Yi-Jen ;

Cooper, Harry S. ;

Deming, Dustin ;

Engstrom, Paul F. ;

Enzinger, Peter C. ;

Fichera, Alessandro ;

Grem, Jean L. ;

Grothey, Axel ;

Hochster, Howard S. ;

Hoffe, Sarah ;

Hunt, Steven ;

Kamel, Ahmed ;

Kirilcuk, Natalie ;

Krishnamurthi, Smitha ;

Messersmith, Wells A. ;

Mulcahy, Mary F. ;

Murphy, James D. ;

Nurkin, Steven ;

Saltz, Leonard ;

Sharma, Sunil ;

Shibata, David ;

Skibber, John M. ;

Sofocleous, Constantinos T. ;

Stoffel, Elena M. ;

Stotsky-Himelfarb, Eden ;

Willett, Christopher G. ;

Wu, Christina S. ;

Gregory, Kristina M. ;

Freedman-Cass, Deborah .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (03) :370-398

[4] Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA [J].

Berger, Andreas W. ;

Schwerdel, Daniel ;

Welz, Hanna ;

Marienfeld, Ralf ;

Schmidt, Stefan A. ;

Kleger, Alexander ;

Ettrich, Thomas J. ;

Seufferlein, Thomas .

PLOS ONE, 2017, 12 (03)

[5] PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].

BOS, JL ;

FEARON, ER ;

HAMILTON, SR ;

VERLAANDEVRIES, M ;

VANBOOM, JH ;

VANDEREB, AJ ;

VOGELSTEIN, B .

NATURE, 1987, 327 (6120) :293-297

[6] Radiofrequency ablation versus resection for resectable liver metastases of gastrointestinal stromal tumours: Results from three national centres in China [J].

Chen, Qichen ;

Li, Cong ;

Yang, Han ;

Zhao, Hong ;

Zhao, Jianjun ;

Bi, Xinyu ;

Li, Zhiyu ;

Huang, Zhen ;

Zhang, Yefan ;

Zhou, Jianguo ;

Cai, Jianqiang .

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (03) :317-323

[7] Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019 [J].

Christou, Niki ;

Meyer, Jeremy ;

Popeskou, Sotirios ;

David, Valentin ;

Toso, Christian ;

Buchs, Nicolas ;

Liot, Emilie ;

Robert, Joan ;

Ris, Frederic ;

Mathonnet, Muriel .

BIOMED RESEARCH INTERNATIONAL, 2019, 2019

[8] Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab [J].

De Roock, Wendy ;

Jonker, Derek J. ;

Di Nicolantonio, Federica ;

Sartore-Bianchi, Andrea ;

Tu, Dongsheng ;

Siena, Salvatore ;

Lamba, Simona ;

Arena, Sabrina ;

Frattini, Milo ;

Piessevaux, Hubert ;

Van Cutsem, Eric ;

O'Callaghan, Chris J. ;

Khambata-Ford, Shirin ;

Zalcberg, John R. ;

Simes, John ;

Karapetis, Christos S. ;

Bardelli, Alberto ;

Tejpar, Sabine .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (16) :1812-1820

[9] KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer [J].

Deng, Yanhong ;

Wang, Li ;

Tan, Shuyun ;

Kim, George P. ;

Dou, Ruoxu ;

Chen, Dianke ;

Cai, Yue ;

Fu, Xinhui ;

Wang, Lei ;

Zhu, Jun ;

Wang, Jianping .

MOLECULAR ONCOLOGY, 2015, 9 (07) :1341-1347

[10] Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care [J].

El Messaoudi, Safia ;

Mouliere, Florent ;

Du Manoir, Stanislas ;

Bascoul-Mollevi, Caroline ;

Gillet, Brigitte ;

Nouaille, Michelle ;

Fiess, Catherine ;

Crapez, Evelyne ;

Bibeau, Frederic ;

Theillet, Charles ;

Mazard, Thibault ;

Pezet, Denis ;

Mathonnet, Muriel ;

Ychou, Marc ;

Thierry, Alain R. .

CLINICAL CANCER RESEARCH, 2016, 22 (12) :3067-3077

← 1 2 3 4 5 6 7 →